Lv4
445 积分 2021-11-11 加入
天下本无事，庸人自扰之~
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma
1天前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
4天前
已完结
Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
14天前
已完结
Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
14天前
已完结
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
28天前
已完结
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
28天前
已完结
Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening
1个月前
已完结
Biomarkers as drug development tools: discovery, validation, qualification and use
1个月前
已完结
A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L)
2个月前
已完结
Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)
2个月前
已完结
皖公网安备34019202002308
